The biobank for the molecular classification of kidney disease: research translation and precision medicine in nephrology
| dc.contributor.author | Muruve, Daniel A | |
| dc.contributor.author | Mann, Michelle C | |
| dc.contributor.author | Chapman, Kevin | |
| dc.contributor.author | Wong, Josee F | |
| dc.contributor.author | Ravani, Pietro | |
| dc.contributor.author | Page, Stacey A | |
| dc.contributor.author | Benediktsson, Hallgrimur | |
| dc.date.accessioned | 2018-09-26T12:02:04Z | |
| dc.date.available | 2018-09-26T12:02:04Z | |
| dc.date.issued | 2017-07-26 | |
| dc.date.updated | 2018-09-26T12:02:04Z | |
| dc.description.abstract | Abstract Background Advances in technology and the ability to interrogate disease pathogenesis using systems biology approaches are exploding. As exemplified by the substantial progress in the personalized diagnosis and treatment of cancer, the application of systems biology to enable precision medicine in other disciplines such as Nephrology is well underway. Infrastructure that permits the integration of clinical data, patient biospecimens and advanced technologies is required for institutions to contribute to, and benefit from research in molecular disease classification and to devise specific and patient-oriented treatments. Methods and results We describe the establishment of the Biobank for the Molecular Classification of Kidney Disease (BMCKD) at the University of Calgary, Alberta, Canada. The BMCKD consists of a fully equipped wet laboratory, an information technology infrastructure, and a formal operational, ethical and legal framework for banking human biospecimens and storing clinical data. The BMCKD first consolidated a large retrospective cohort of kidney biopsy specimens to create a population-based renal pathology database and tissue inventory of glomerular and other kidney diseases. The BMCKD will continue to prospectively bank all kidney biopsies performed in Southern Alberta. The BMCKD is equipped to perform molecular, clinical and epidemiologic studies in renal pathology. The BMCKD also developed formal biobanking procedures for human specimens such as blood, urine and nucleic acids collected for basic and clinical research studies or for advanced diagnostic technologies in clinical care. The BMCKD is guided by standard operating procedures, an ethics framework and legal agreements with stakeholders that include researchers, data custodians and patients. The design and structure of the BMCKD permits its inclusion in a wide variety of research and clinical activities. Conclusion The BMCKD is a core multidisciplinary facility that will bridge basic and clinical research and integrate precision medicine into renal pathology and nephrology. | |
| dc.identifier.citation | BMC Nephrology. 2017 Jul 26;18(1):252 | |
| dc.identifier.doi | https://doi.org/10.1186/s12882-017-0669-4 | |
| dc.identifier.uri | http://hdl.handle.net/1880/107896 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/45130 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s). | |
| dc.title | The biobank for the molecular classification of kidney disease: research translation and precision medicine in nephrology | |
| dc.type | Journal Article |